Compare Infosys Limited (INFY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Repligen Corporation Common Stock — how do they compare? Infosys Limited trades at $11.75 (market cap $46.25B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Infosys Limited is far larger — about 4.1× Repligen Corporation Common Stock's market cap, and Infosys Limited pays a 4.56% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Repligen Corporation Common Stock for 0 Days on average.
| INFY | RGEN | |
|---|---|---|
Market Cap | $46.25B | $11.31B |
Volume | 14,209,421 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $20.22 | $194.57 |
52-Week Low | $10.49 | $102.87 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $44.00B | $11.20B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal and strong profitability metrics including a 16.37% net margin and 32.12% ROE. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, signaling growth initiatives.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering modest upside. Risks include potential earnings volatility and competitive pressures in IT services. Analyst sentiment is mixed with 35% buy ratings, but strong cash flow and institutional interest support a stable investment case amid sector headwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
